Triple-Negative Breast Cancer (TNBC) is a particularly aggressive subtype among breast
cancers (BCs), characterized by anoikis resistance, high invasiveness, and metastatic …

Triple-negative breast cancer (TNBC) shows a higher malignant and poorer clinical outcome
compared with other breast cancer subtypes. Albeit that chemotherapy is the first choice for …

Triple negative breast cancers (TNBCs) represent a distinct subtype of breast cancers that
are associated with early recurrence and an aggressive metastatic progression of the …

Breast cancer is the second-most frequently diagnosed malignancy in US women. The triple-
negative breast cancer (TNBC) subtype, which lacks expression of the estrogen receptor …

Background Triple-negative breast cancer (TNBC) is a poor prognostic breast cancer with
the highest mutations and limited therapeutic choices. Cytokine networking between cancer …

Background Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast
cancer with a high probability of metastasis and a lack of specific targets and targeted …

High levels of the anti-apoptotic BCL-2 family member MCL-1 are frequently found in breast
cancer and, appropriately, BH3-mimetic drugs that specifically target MCL-1's function in …

Triple-negative breast cancer (TNBC) is an exceptionally aggressive subtype of breast
cancer. Despite the recognized interplay between tumors and tumor-associated …

Background Triple negative breast cancers (TNBC) possess cell dedifferentiation
characteristics, carry out activities connate to those of cancer stem cells (CSCs) and are …

Triple‐negative breast cancer (TNBC) is highly metastatic and frequently has a poor
prognosis. The lack of comprehension of TNBC and gene therapy targets has led to limitedly …